STTK

NASDAQ

Shattuck Labs Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2020

News25/Ratings12

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

News · 26 weeks32-50%

2025-10-262026-04-19

Mix1490d

SEC Filings5(36%)
Insider4(29%)
Other3(21%)
Analyst2(14%)

Latest news

25 items

15dSEC
SEC Form DEFA14A filed by Shattuck Labs Inc.
DEFA14A - Shattuck Labs, Inc. (0001680367) (Filer)
15dSEC
SEC Form DEF 14A filed by Shattuck Labs Inc.
DEF 14A - Shattuck Labs, Inc. (0001680367) (Filer)
48dANALYST
Needham resumed coverage on Shattuck Labs with a new price target
Needham resumed coverage of Shattuck Labs with a rating of Buy and set a new price target of $25.00
49dSEC
SEC Form 10-K filed by Shattuck Labs Inc.
10-K - Shattuck Labs, Inc. (0001680367) (Filer)
49dSEC
Shattuck Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Shattuck Labs, Inc. (0001680367) (Filer)
49dPR
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter of 2026 – AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided recent business highlights. "
57dPR
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details TD Cowen 46th Annual Health Care Conference Format: Corporate presentation and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive OfficerPresentation Date: March 2, 2026Time: 9:10 AM ETLocation: Bos
76dPR
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium, taking place February 12-13, 2026. Conference Details Conference: Piper Sandler Virtual Novel Targets in Immunology SymposiumFormat: Fireside chat Presenters: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, Andr
77dSEC
SEC Form 8-K filed by Shattuck Labs Inc.
8-K - Shattuck Labs, Inc. (0001680367) (Filer)
85dANALYST
Piper Sandler initiated coverage on Shattuck Labs with a new price target
Piper Sandler initiated coverage of Shattuck Labs with a rating of Overweight and set a new price target of $15.00
86dINSIDER
Chief Medical Officer Pandite Arundathy N. covered exercise/tax liability with 3,195 shares, decreasing direct ownership by 2% to 196,219 units (SEC Form 4)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
86dINSIDER
Officer Stout Stephen covered exercise/tax liability with 593 shares, decreasing direct ownership by 0.72% to 81,529 units (SEC Form 4)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
86dINSIDER
Chief Business Officer Deyoung Casi covered exercise/tax liability with 2,286 shares, decreasing direct ownership by 3% to 73,480 units (SEC Form 4)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
86dINSIDER
Chief Financial Officer Neill Andrew R covered exercise/tax liability with 2,589 shares, decreasing direct ownership by 1% to 228,224 units (SEC Form 4)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
91dSEC
SEC Form 8-K filed by Shattuck Labs Inc.
8-K - Shattuck Labs, Inc. (0001680367) (Filer)
91dSEC
SEC Form 424B5 filed by Shattuck Labs Inc.
424B5 - Shattuck Labs, Inc. (0001680367) (Filer)
91dSEC
SEC Form EFFECT filed by Shattuck Labs Inc.
EFFECT - Shattuck Labs, Inc. (0001680367) (Filer)
100dINSIDER
Officer Stout Stephen covered exercise/tax liability with 4,153 shares, decreasing direct ownership by 5% to 82,122 units (SEC Form 4)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
100dINSIDER
Chief Business Officer Deyoung Casi covered exercise/tax liability with 5,699 shares, decreasing direct ownership by 7% to 75,766 units (SEC Form 4)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
100dINSIDER
SEC Form 4 filed by Chief Technical Officer Shukla Abhinav A.
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
100dINSIDER
Chief Medical Officer Pandite Arundathy N. covered exercise/tax liability with 6,851 shares, decreasing direct ownership by 3% to 199,414 units (SEC Form 4)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
100dINSIDER
Chief Financial Officer Neill Andrew R covered exercise/tax liability with 6,660 shares, decreasing direct ownership by 3% to 230,813 units (SEC Form 4)
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
100dINSIDER
SEC Form 4 filed by Chief Executive Officer Schreiber Taylor
4 - Shattuck Labs, Inc. (0001680367) (Issuer)
100dSEC
SEC Form S-3 filed by Shattuck Labs Inc.
S-3 - Shattuck Labs, Inc. (0001680367) (Filer)
129dPR
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on December 10, 2025 (the "Grant Date") to a newly-hired non-executive officer. The inducement awards consist of non-qualified stock options to purchase 206,000 shares of Shattuck's common stock with an exercise price of $3.23 per share. The stock options have a maximum term of 10 ye